Trial · NCT01247090
Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
NCT01247090, Phase 2, Completed, Columbia University; results first posted 2011-04-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease. Trials, record NCT01247090. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01247090
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
- NCT number
- NCT01247090
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Columbia University
- Conditions
- Hypertension, End Stage Renal Disease
- Interventions
- Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator
- First posted
- 2010-11-24
- Last updated
- 2019-11-18
- Results first posted
- 2011-04-28
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period | Baseline and Two Weeks | This is designed to measure if the administration of intradialytic AVP will result in change in systolic blood pressure. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period | Baseline and Two Weeks | mm Hg | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period | Very Low Dose | -1.5 | Standard Deviation 8.6 | mm Hg | |
| Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period | Low Dose | -3.7 | Standard Deviation 27.0 | mm Hg | |
| Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period | Placebo | -0.4 | Standard Deviation 11.8 | mm Hg |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Very Low Dose | 4 | |
| Overall Study | STARTED | Low Dose | 4 | |
| Overall Study | STARTED | Placebo | 4 | |
| Overall Study | COMPLETED | Very Low Dose | 3 | |
| Overall Study | COMPLETED | Low Dose | 3 | |
| Overall Study | COMPLETED | Placebo | 4 | |
| Overall Study | NOT COMPLETED | Very Low Dose | 1 | |
| Overall Study | NOT COMPLETED | Low Dose | 1 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Very Low Dose | 0 | 4 |
| Total, all-cause mortality | Low Dose | 0 | 4 |
| Total, all-cause mortality | Placebo | 0 | 4 |
| Total, other adverse events | Very Low Dose | 0 | 4 |
| Total, other adverse events | Low Dose | 0 | 4 |
| Total, other adverse events | Placebo | 0 | 4 |
| Total, serious adverse events | Very Low Dose | 0 | 4 |
| Total, serious adverse events | Low Dose | 0 | 4 |
| Total, serious adverse events | Placebo | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01247090
GET https://conductscience.org/api/trials/v1/NCT01247090/registered